Molecular Basis of Canavan's Disease
- 1 September 2003
- journal article
- other
- Published by SAGE Publications in Journal of Child Neurology
- Vol. 18 (9) , 604-610
- https://doi.org/10.1177/08830738030180090601
Abstract
Canavan's disease is an autosomal recessive disorder caused by aspartoacylase deficiency. The deficiency of aspartoacylase leads to increased concentration of N-acetylaspartic acid in brain and body fluids. The failure to hydrolyze N-acetylaspartic acid causes disruption of myelin, resulting in spongy degeneration of the white matter of the brain. The clinical features of the disease are hypotonia in early life, which changes to spasticity, macrocephaly, head lag, and progressive severe mental retardation. Although Canavan's disease is panethnic, it is most prevalent in the Ashkenazi Jewish population. Research at the molecular level led to the cloning of the gene for aspartoacylase and development of a knockout mouse for Canavan's disease. These developments have afforded new tools for research in the attempts to understand the pathophysiology of Canavan's disease, design new therapies, and explore methods for gene transfer to the central nervous system. (J Child Neurol 2003;18:604—610).Keywords
This publication has 30 references indexed in Scilit:
- Two novel aspartoacylase gene (ASPA) missense mutations specific to Norwegian and Swedish patients with Canavan diseaseJournal of Medical Genetics, 2002
- A benign polymorphism in the aspartoacylase gene may cause misinterpretation of Canavan gene testingEuropean Journal of Human Genetics, 1998
- Gene Transfer by Adeno-Associated Virus Vectors into the Central Nervous SystemExperimental Neurology, 1997
- Implications of apoptotic cell death regulation in cancer therapySeminars in Cancer Biology, 1995
- Herpes simplex virus vectors for gene therapyMolecular Biotechnology, 1994
- Canavan Disease: Genomic Organization and Localization of Human ASPA to 17p13-ter and Conservation of the ASPA Gene during EvolutionGenomics, 1994
- Cloning of the human aspartoacylase cDNA and a common missense mutation in Canavan diseaseNature Genetics, 1993
- In vivo assessment of N-acetylaspartate in brain in spongy degeneration (Canavan's disease) by proton spectroscopyThe Lancet, 1990
- Aspartoacylase deficiency and N‐acetylaspartic aciduria in patients with canavan diseaseAmerican Journal of Medical Genetics, 1988
- Computed tomography in the diagnosis of Canavan's diseaseAnnals of Neurology, 1981